Friday 16 October 2026 Export AVXL’s income statement to Excel — free account

Anavex Life Sciences Corp.

In the quarter to June 2026, EPS grew 150.0% and free cash flow grew 27.0%, each against the same quarter a year earlier.

1.34 0.14 −9.46%

Follow AVXL

Alert me

Market cap: $137.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.70%

Capital & Financial Ratios $m

Market Cap 137.19

Revenue —

Net Income (13.02)

Free Cash Flow (29.29)

Net Debt (118.33)

Current Ratio 15.62

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.22

Past 5Y EPS Growth —

This Y EPS Growth 38.89%

Next Y EPS Growth (66.67%)

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 0.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	151	132	103	118
Receivables	3	2	1	1
Inventory	—	—	—	—
Other	—	—	—	—
	154	136	104	120

	2023	2024	2025	Q'26
Payables	4	10	4	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	13	15	9	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	22.17%	28.35%	(12.68%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(7)	(4)	(9)	—	—
’25	(12)	(6)	(12)	(9)	(39)
’24	(7)	(12)	(5)	(7)	(31)
’23	(6)	(8)	(8)	(6)	(28)
’22	(4)	(10)	(7)	(4)	(24)
’21	(8)	(7)	(8)	(8)	(30)
’20	(6)	(5)	(4)	(6)	(21)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(7)	(4)	(9)	—	—
’25	(12)	(6)	(12)	(9)	(39)
’24	(7)	(12)	(5)	(7)	(31)
’23	(6)	(8)	(8)	(6)	(28)
’22	(4)	(10)	(7)	(4)	(24)
’21	(8)	(7)	(8)	(8)	(30)
’20	(6)	(5)	(4)	(6)	(21)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.06)	(0.06)	0.08	—	—
’25	(0.14)	(0.13)	(0.16)	(0.11)	(0.54)
’24	(0.11)	(0.13)	(0.14)	(0.14)	(0.52)
’23	(0.17)	(0.17)	(0.14)	(0.12)	(0.60)
’22	(0.14)	(0.14)	(0.16)	(0.18)	(0.62)
’21	(0.12)	(0.12)	(0.14)	(0.15)	(0.54)
’20	(0.12)	(0.12)	(0.11)	(0.10)	(0.45)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.43	3.01	1.25	1.48	2.20	5.12	7.13	4.90	3.25	2.86	Analyst estimates 2026–2028 Powerpack
	High	8.30	6.64	4.35	4.09	7.69	31.50	18.19	11.93	14.44	14.25
People
People	Employees	10	10	13	16	20	25	38	40	42	34
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	—	—	—	—	—	—	—	—	—
	EBT	(15)	(13)	(17)	(26)	(26)	(38)	(48)	(48)	(43)	(46)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(15)	(13)	(17)	(26)	(26)	(38)	(48)	(48)	(43)	(46)
	Depreciation	0	—	—	0	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.42)	(0.33)	(0.39)	(0.54)	(0.45)	(0.54)	(0.62)	(0.60)	(0.52)	(0.54)
	Cash flow	(0.26)	(0.22)	(0.28)	(0.38)	(0.37)	(0.44)	(0.32)	(0.35)	(0.37)	(0.46)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.26)	(0.22)	(0.28)	(0.38)	(0.37)	(0.44)	(0.32)	(0.35)	(0.37)	(0.46)
	Book value	0.18	0.59	0.50	0.41	0.47	2.16	1.85	1.78	1.44	1.11
	Shares, m	35	41	45	49	58	70	77	80	83	85
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(9)	(9)	(13)	(19)	(21)	(30)	(24)	(28)	(31)	(39)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	(9)	(9)	(13)	(19)	(21)	(30)	(24)	(28)	(31)	(39)
Balance, $m
Balance, $m	Working capital	6	24	22	20	27	151	142	142	120	95
	Total debt	—	—	—	—	—	—	—	—	—	—
	Net debt	(9)	(27)	(23)	(22)	(29)	(152)	(149)	(151)	(132)	(103)
	Shareholders’ equity	6	24	22	20	27	151	142	142	120	95
Returns, %
Returns, %	ROA	(118.04)	(72.10)	(63.85)	(102.05)	(87.79)	(38.65)	(30.53)	(30.94)	(29.66)	(38.75)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(154.17)	(88.09)	(74.08)	(123.42)	(110.59)	(42.58)	(32.71)	(33.41)	(32.81)	(43.11)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CDXS Codexis, Inc.	$148.9M	— (loss-making)	— (loss-making)	−2.69% (below 0%: shrinking)	n/m	+48.60% (above 0%: growing)	76.45%	(75.29%)	Compare
MSLE Satellos Bioscience Inc.	$145.1M	— (loss-making)	—	—	n/m	−65.66% (below 0%: shrinking)	99.26%	0.00%	Compare
MOLN Molecular Partners AG Sponsored ADR	$143.5M	— (loss-making)	— (loss-making)	−98.86% (below 0%: shrinking)	n/m	+23.77% (above 0%: growing)	0.00%	0.00%	Compare
ALXO ALX Oncology Holdings Inc.	$138.3M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+31.65% (above 0%: growing)	0.00%	0.00%	Compare
AVXL Anavex Life Sciences Corp.	$137.2M	— (loss-making)	—	—	n/m	+27.02% (above 0%: growing)	—	0.00%
ANTX AN2 Therapeutics, Inc.	$135.9M	— (loss-making)	—	—	n/m	+7.91% (above 0%: growing)	0.00%	0.00%	Compare
CUE Cue Biopharma, Inc.	$135.6M	— (loss-making)	— (loss-making)	+166.66% (above 0%: growing)	n/m	−742.65% (below 0%: shrinking)	100.00%	(1,113.30%)	Compare
TLSA Tiziana Life Sciences Ltd	$134.7M	— (loss-making)	—	—	−258.11% (below 0%: shrinking)	+18.03% (above 0%: growing)	0.00%	—	Compare
ABOS Acumen Pharmaceuticals, Inc.	$120.8M	— (loss-making)	—	—	n/m	+43.23% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$137.1M	—	—	−50.77%	—	+20.90%	0.00%	0.00%

All 614 Biotechnology stocks →

Anavex Life Sciences Corp. (AVXL) key facts

Anavex Life Sciences Corp. (AVXL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 15, 2026, AVXL traded at $1.48, a market capitalization of $137.2 million.
Return on equity was −43.1% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.